-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Japanese -X- _ B-Patient
encephalitis -X- _ I-Patient
( -X- _ I-Patient
JE -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
caused -X- _ O
by -X- _ O
a -X- _ O
mosquito-borne -X- _ O
flavivirus -X- _ O
, -X- _ O
is -X- _ O
endemic -X- _ O
to -X- _ O
the -X- _ O
entire -X- _ O
south-east -X- _ O
Asian -X- _ O
and -X- _ O
adjoining -X- _ O
regions. -X- _ O
Currently -X- _ O
no -X- _ O
therapeutic -X- _ O
interventions -X- _ O
are -X- _ O
available -X- _ O
for -X- _ O
JE -X- _ O
, -X- _ O
thereby -X- _ O
making -X- _ O
it -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
dreaded -X- _ O
encephalitides -X- _ O
in -X- _ O
the -X- _ O
world. -X- _ O
An -X- _ O
effective -X- _ O
way -X- _ O
to -X- _ O
counter -X- _ O
the -X- _ O
virus -X- _ O
would -X- _ O
be -X- _ O
to -X- _ O
inhibit -X- _ O
viral -X- _ O
replication -X- _ O
by -X- _ O
using -X- _ O
anti-sense -X- _ O
molecules -X- _ O
directed -X- _ O
against -X- _ O
the -X- _ O
viral -X- _ O
genome. -X- _ O
Octaguanidinium -X- _ B-Intervention
dendrimer-conjugated -X- _ I-Intervention
Morpholino -X- _ I-Intervention
( -X- _ I-Intervention
or -X- _ I-Intervention
Vivo-Morpholino -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
uncharged -X- _ O
anti-sense -X- _ O
oligomers -X- _ O
that -X- _ O
can -X- _ O
enter -X- _ O
cells -X- _ O
of -X- _ O
living -X- _ O
organisms -X- _ O
by -X- _ O
endocytosis -X- _ O
and -X- _ O
subsequently -X- _ O
escape -X- _ O
from -X- _ O
endosomes -X- _ O
into -X- _ O
the -X- _ O
cytosol -X- _ O
/ -X- _ O
nuclear -X- _ O
compartment -X- _ O
of -X- _ O
cells. -X- _ O
We -X- _ O
hypothesize -X- _ O
that -X- _ O
Vivo-Morpholinos -X- _ B-Intervention
generated -X- _ O
against -X- _ O
specific -X- _ O
regions -X- _ O
of -X- _ O
3′ -X- _ O
or -X- _ O
5′ -X- _ O
untranslated -X- _ O
regions -X- _ O
of -X- _ O
JEV -X- _ O
genome -X- _ O
, -X- _ O
when -X- _ O
administered -X- _ O
in -X- _ O
an -X- _ O
experimental -X- _ O
model -X- _ O
of -X- _ O
JE -X- _ B-Patient
, -X- _ O
will -X- _ O
have -X- _ O
significant -X- _ O
antiviral -X- _ O
and -X- _ O
neuroprotective -X- _ O
effect. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
Mice -X- _ B-Patient
were -X- _ I-Patient
infected -X- _ I-Patient
with -X- _ I-Patient
JEV -X- _ I-Patient
( -X- _ I-Patient
GP78 -X- _ I-Patient
strain -X- _ I-Patient
) -X- _ I-Patient
followed -X- _ O
by -X- _ O
intraperitoneal -X- _ B-Intervention
administration -X- _ I-Intervention
of -X- _ I-Intervention
Morpholinos -X- _ I-Intervention
( -X- _ I-Intervention
5 -X- _ I-Intervention
mg -X- _ I-Intervention
/ -X- _ I-Intervention
kg -X- _ I-Intervention
body -X- _ I-Intervention
weight -X- _ I-Intervention
) -X- _ I-Intervention
daily -X- _ I-Intervention
for -X- _ I-Intervention
up -X- _ I-Intervention
to -X- _ I-Intervention
five -X- _ I-Intervention
treatments. -X- _ I-Intervention
Survivability -X- _ O
of -X- _ O
the -X- _ O
animals -X- _ O
was -X- _ O
monitored -X- _ O
for -X- _ O
15 -X- _ O
days -X- _ O
( -X- _ O
or -X- _ O
until -X- _ O
death -X- _ O
) -X- _ O
following -X- _ O
which -X- _ O
they -X- _ O
were -X- _ O
sacrificed -X- _ O
and -X- _ O
their -X- _ O
brains -X- _ O
were -X- _ O
processed -X- _ O
either -X- _ O
for -X- _ O
immunohistochemical -X- _ O
staining -X- _ O
or -X- _ O
protein -X- _ O
extraction. -X- _ O
Plaque -X- _ O
assay -X- _ O
and -X- _ O
immunoblot -X- _ O
analysis -X- _ O
performed -X- _ O
from -X- _ O
brain -X- _ O
homogenates -X- _ O
showed -X- _ O
reduced -X- _ B-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
protein -X- _ I-Outcome
expression -X- _ I-Outcome
, -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
greater -X- _ I-Outcome
survival -X- _ I-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
animals. -X- _ I-Outcome
Neuroprotective -X- _ I-Outcome
effect -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
by -X- _ I-Outcome
thionin -X- _ I-Outcome
staining -X- _ I-Outcome
of -X- _ I-Outcome
brain -X- _ I-Outcome
sections. -X- _ I-Outcome
Cytokine -X- _ I-Outcome
bead -X- _ I-Outcome
array -X- _ I-Outcome
showed -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
proinflammatory -X- _ I-Outcome
cytokines -X- _ I-Outcome
in -X- _ I-Outcome
brain -X- _ I-Outcome
following -X- _ I-Outcome
Morpholino -X- _ I-Outcome
treatment -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
were -X- _ I-Outcome
elevated -X- _ I-Outcome
after -X- _ I-Outcome
infection. -X- _ I-Outcome
This -X- _ I-Outcome
corresponded -X- _ I-Outcome
to -X- _ I-Outcome
reduced -X- _ I-Outcome
microglial -X- _ I-Outcome
activation -X- _ I-Outcome
in -X- _ I-Outcome
brain. -X- _ I-Outcome
Oxidative -X- _ I-Outcome
stress -X- _ I-Outcome
was -X- _ I-Outcome
reduced -X- _ I-Outcome
and -X- _ I-Outcome
certain -X- _ I-Outcome
stress-related -X- _ I-Outcome
signaling -X- _ I-Outcome
molecules -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
positively -X- _ I-Outcome
modulated -X- _ I-Outcome
following -X- _ I-Outcome
Morpholino -X- _ I-Outcome
treatment. -X- _ I-Outcome
In -X- _ I-Outcome
vitro -X- _ I-Outcome
studies -X- _ I-Outcome
also -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
decrease -X- _ I-Outcome
in -X- _ I-Outcome
infective -X- _ I-Outcome
viral -X- _ I-Outcome
particle -X- _ I-Outcome
production -X- _ I-Outcome
following -X- _ I-Outcome
Morpholino -X- _ I-Outcome
treatment. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Administration -X- _ O
of -X- _ O
Vivo-Morpholino -X- _ B-Intervention
effectively -X- _ O
resulted -X- _ B-Outcome
in -X- _ I-Outcome
increased -X- _ I-Outcome
survival -X- _ I-Outcome
of -X- _ I-Outcome
animals -X- _ I-Outcome
and -X- _ I-Outcome
neuroprotection -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
murine -X- _ I-Outcome
model -X- _ I-Outcome
of -X- _ I-Outcome
JE. -X- _ I-Outcome
Hence -X- _ O
, -X- _ O
these -X- _ O
oligomers -X- _ O
represent -X- _ O
a -X- _ O
potential -X- _ O
antiviral -X- _ O
agent -X- _ O
that -X- _ O
merits -X- _ O
further -X- _ O
evaluation -X- _ O
. -X- _ O

